Functional Selectivity of Coumarin Derivates Acting via GPR55 in Neuroinflammation.
Animals
Anti-Inflammatory Agents
/ chemical synthesis
Cell Line
Cell Proliferation
/ drug effects
Cell Survival
/ drug effects
Cells, Cultured
Coumarins
/ chemical synthesis
Dinoprostone
/ metabolism
Humans
Mice
Microglia
/ cytology
Neurons
/ cytology
Organ Specificity
Primary Cell Culture
Receptors, Cannabinoid
/ metabolism
GPR55
PGE2
SK-N-SH
coumarin derivates
functional selectivity
neuroinflammation
primary microglia
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
16 Jan 2022
16 Jan 2022
Historique:
received:
24
12
2021
revised:
09
01
2022
accepted:
13
01
2022
entrez:
21
1
2022
pubmed:
22
1
2022
medline:
9
2
2022
Statut:
epublish
Résumé
Anti-neuroinflammatory treatment has gained importance in the search for pharmacological treatments of different neurological and psychiatric diseases, such as depression, schizophrenia, Parkinson's disease, and Alzheimer's disease. Clinical studies demonstrate a reduction of the mentioned diseases' symptoms after the administration of anti-inflammatory drugs. Novel coumarin derivates have been shown to elicit anti-neuroinflammatory effects via G-protein coupled receptor GPR55, with possibly reduced side-effects compared to the known anti-inflammatory drugs. In this study, we, therefore, evaluated the anti-inflammatory capacities of the two novel coumarin-based compounds, KIT C and KIT H, in human neuroblastoma cells and primary murine microglia. Both compounds reduced PGE
Identifiants
pubmed: 35055142
pii: ijms23020959
doi: 10.3390/ijms23020959
pmc: PMC8779649
pii:
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Coumarins
0
GPR55 protein, human
0
Receptors, Cannabinoid
0
Dinoprostone
K7Q1JQR04M
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : 266379491
Références
Nat Rev Drug Discov. 2013 Mar;12(3):205-16
pubmed: 23411724
Kidney Res Clin Pract. 2015 Dec;34(4):194-200
pubmed: 26779421
J Ethnopharmacol. 2014 Mar 14;152(2):377-83
pubmed: 24491645
Front Pharmacol. 2020 Jul 08;11:1002
pubmed: 32733244
Cancer Lett. 2020 Jul 10;482:102-111
pubmed: 31705927
Expert Opin Ther Targets. 2005 Oct;9(5):887-900
pubmed: 16185146
Int J Mol Sci. 2021 Mar 17;22(6):
pubmed: 33803038
J Med Chem. 2013 Jun 13;56(11):4798-810
pubmed: 23679955
FASEB J. 2019 Jan;33(1):1299-1312
pubmed: 30148676
Brain Res Mol Brain Res. 1999 Feb 5;64(2):193-8
pubmed: 9931487
Brain Behav Immun. 2019 Feb;76:165-181
pubmed: 30465881
J Neuroinflammation. 2018 Nov 19;15(1):322
pubmed: 30453998
Neurobiol Dis. 2021 May;152:105301
pubmed: 33609641
Exp Neurol. 2007 Jun;205(2):295-312
pubmed: 17433296
Brain Commun. 2020 Jul 24;2(2):fcaa109
pubmed: 33134914
Neuropharmacology. 2017 Oct;125:319-332
pubmed: 28807673
Acta Psychiatr Scand. 2019 May;139(5):404-419
pubmed: 30834514
Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16511-6
pubmed: 19805329
Front Pharmacol. 2015 Apr 15;6:69
pubmed: 25926795
J Neuroimmunol. 2006 May;174(1-2):39-51
pubmed: 16529823
J Med Chem. 2012 Sep 27;55(18):7967-77
pubmed: 22916707
Antioxidants (Basel). 2020 Jul 22;9(8):
pubmed: 32707949
Int J Mol Sci. 2021 Dec 03;22(23):
pubmed: 34884889
J Neuroinflammation. 2017 Dec 13;14(1):246
pubmed: 29237478
Pediatr Res. 2012 Nov;72(5):460-7
pubmed: 22926547
Synapse. 2011 Feb;65(2):103-8
pubmed: 20506567
Mol Pharmacol. 2007 Dec;72(6):1393-401
pubmed: 17901198
Adv Biol Regul. 2016 Jan;60:88-93
pubmed: 26588872
Br J Pharmacol. 2007 Dec;152(7):1092-101
pubmed: 17876302
Eur Child Adolesc Psychiatry. 2019 Oct;28(10):1395-1405
pubmed: 30843122
Biochem Biophys Res Commun. 2007 Nov 3;362(4):928-34
pubmed: 17765871
Br J Pharmacol. 2010 Jun;160(3):604-14
pubmed: 20136841
Inflamm Bowel Dis. 2011 Aug;17(8):1651-64
pubmed: 21744421
J Neurosci. 1989 Jan;9(1):183-94
pubmed: 2643682
FEBS Lett. 2015 Jun 22;589(14):1607-19
pubmed: 25980603
J Neuroinflammation. 2013 Apr 01;10:43
pubmed: 23547920
Glia. 2005 Aug 15;51(3):199-208
pubmed: 15800925
Biomaterials. 2007 Jun;28(18):2915-22
pubmed: 17363051
Cell Mol Neurobiol. 2014 Jan;34(1):31-42
pubmed: 24030360
Diabetes. 2012 Feb;61(2):281-91
pubmed: 22179809
Proc Natl Acad Sci U S A. 1991 Sep 15;88(18):8169-73
pubmed: 1896465
Neurotherapeutics. 2018 Jul;15(3):796-806
pubmed: 29435814
Front Pharmacol. 2021 Nov 17;12:789074
pubmed: 34867421
PLoS Pathog. 2020 Oct 15;16(10):e1009006
pubmed: 33057440
Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2699-704
pubmed: 18263732
Mol Neurobiol. 2019 Nov;56(11):7741-7753
pubmed: 31111399
Proc Natl Acad Sci U S A. 2019 May 14;116(20):10019-10024
pubmed: 31036664
Fundam Clin Pharmacol. 2015 Apr;29(2):185-90
pubmed: 25620584
Phytomedicine. 2004 Feb;11(2-3):135-8
pubmed: 15070163
World J Transplant. 2021 Nov 18;11(11):443-465
pubmed: 34868896
Pain. 2008 Sep 30;139(1):225-236
pubmed: 18502582
Acta Neuropsychiatr. 2021 Feb;33(1):15-21
pubmed: 32967746
Pharmacol Rev. 1996 Sep;48(3):413-63
pubmed: 8888308
Glia. 2008 Jun;56(8):844-55
pubmed: 18383341
Biology (Basel). 2020 Nov 05;9(11):
pubmed: 33167441
Neuropsychopharmacology. 2015 Mar;40(4):1037-51
pubmed: 25374096
Int J Mol Sci. 2021 Mar 02;22(5):
pubmed: 33801492
Br J Gen Pract. 2016 Apr;66(645):172-3
pubmed: 27033477
Eur J Neurosci. 2021 Jan;53(1):151-171
pubmed: 32150310
PLoS One. 2008 Jul 23;3(7):e2718
pubmed: 18648507
FASEB J. 2009 Jan;23(1):183-93
pubmed: 18757503
Int J Mol Sci. 2021 Oct 28;22(21):
pubmed: 34769094
J Immunol. 2010 Nov 1;185(9):5300-14
pubmed: 20921530